Aug 2026· European Urology Oncology· 2 citations· 11 references
Medicine
TL;DR
Improving access to high-quality PSMA PET should be regarded not only as a logistical objective but also as a clinical priority to ensure that advances in molecular imaging translate into more precise, timely, and equitable PCa care.
Abstract
Prostate-specific membrane antigen positron emission tomography (PSMA PET) has become an integral component of contemporary prostate cancer (PCa) management, improving disease characterization in clinically relevant settings such as initial staging of higher-risk disease and biochemical recurrence. Beyond its superior diagnostic performance compared with conventional imaging, PSMA PET increasingly influences treatment planning, patient stratification, and multidisciplinary decision-making. However, despite growing incorporation into international clinical guidelines, access to PSMA PET remains heterogeneous across health care systems. Variability in reimbursement policies, regulatory frameworks, tracer availability, imaging capacity, referral pathways, and local expertise may limit timely access for eligible patients. These disparities have important clinical implications, potentially affecting staging accuracy, localization of recurrent disease, treatment selection, and equity of care. In this expert perspective, we discuss the evolving role of PSMA PET in PCa management, highlight the clinical consequences of unequal access, and identify key priorities to facilitate implementation across Europe. Improving access to high-quality PSMA PET should be regarded not only as a logistical objective but also as a clinical priority to ensure that advances in molecular imaging translate into more precise, timely, and equitable PCa care.
To examine the gap between evidence-based indications for PSMA PET/CT and real-world access in prostate cancer, with a focus on European implementation and country-specific experience from Spain and France. A focused narrative appraisal of published evidence, clinical guidelines, regulatory and reimbursement informatio...
J. G. Rivas, L. F. Hernández, L. Turpin et al.· World journal of urology· 0 citations
Introduction: Prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) and PSMA radioligand therapy are changing prostate cancer management, but there is ongoing uncertainty regarding how best to incorporate these approaches into routine practice. This expert report provides C...
A. Lalani, Mina M. Swiha, Sharlini Yogasingam et al.· Canadian Urological Associat...· 0 citations
Simple Summary Patients with prostate cancer (PC) may experience a rise in prostate-specific antigen (PSA) after radical prostatectomy (RP) despite having no detectable disease on conventional imaging. In this situation, treatment decisions are often based on clinical risk factors rather than the true location of recur...
Francesco Amorelli, P. Plaza, A. Natali et al.· Cancers· 0 citations
. Biochemically recurrent prostate cancer (BCR) represents a common clinical challenge following definitive local therapy. While traditionally defined by rising prostate-specific antigen (PSA) levels in the absence of metastatic disease on conventional imaging, the advent of prostate-specific membrane antigen (PSMA) PE...
J. Aragon-Ching, R. Madan· The Canadian journal of urol...· 0 citations
Fluorine-18 fluorodeoxyglucose ([18F] FDG) PET/CT has become central to the management of paediatric lymphoma, providing critical information for staging, response assessment, and treatment adaptation. Its integration into international clinical trials and treatment protocols has enabled response-adapted strategies tha...
Akinwale O. Ayeni, Tebatso Tebeila, Mampoi T Jonas et al.· Seminars in nuclear medicine· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.